CNX Therapeutics Ltd

UK specialty pharmaceutical company focused on neurology and CNS, B Corp certified (first UK pharma company to exceed B Corp standards). Commercializes and distributes a portfolio of medicines for neurological, psychiatric, and hospital emergency treatments in 60+ markets worldwide. In October 2025 acquired Sativex® (nabiximols) from Jazz Pharmaceuticals. Backed by Inflexion.